PM Raises Adjusted EPS Forecast for 2026

Philip Morris’s upgraded adjusted EPS projection for 2026 (11.1%–13.1% growth versus 2025) reflects continued scale-up of smoke‑free products and operational leverage from prior cost measures. SFPs accounted for 22.8% of 2025 shipment volume, driven by heat‑not‑burn (HTU) and oral pouch growth: HTU volume rose 11.0% year‑over‑year to 155.1 billion units, and oral SFPs grew 18.5% to 20.7 billion units. E‑vapor doubled on a small base to 3.3 billion units (100% YoY), underlining portfolio diversification. The company’s 2025 income statement shows strong margin conversion: gross profit of $27,282m on $40,648m of revenue (about a 67% gross margin) and operating income of $14,892m (roughly a 36.6% operating margin). Those margins provide room for adjusted EPS upside as higher‑margin SFPs gain share and fixed costs are leveraged across the business. Management’s shift to two operating units (International and U.S.) effective Jan 1, 2026 is intended to improve agility and better capture market dynamics in core SFP growth markets.

The raised adjusted EPS range is a positive signal for investors focused on execution-led growth rather than structural moat expansion. Key investment takeaways: - Growth drivers: Continued IQOS adoption in HTU markets and ZYN momentum in oral nicotine pouches are primary contributors to the EPS upgrade. SFP shipment volume trends (HTU +11.0% and oral +18.5% in 2025) support a higher mix of higher‑margin products. - Financial leverage: With 2025 net earnings of $11,848m and sizable operating margins, incremental SFP volume and pricing can disproportionately benefit adjusted EPS. - Balance sheet and cost pressure: Long‑term debt stands at $45,134m and management reported a stockholders’ deficit of $(8,028)m as of year‑end 2025. Elevated debt and high global interest rates remain considerations for cash‑flow allocation between investment, dividends and deleveraging. - Execution risk: The company’s advantages are described as execution‑based rather than a sustainable structural moat. Competitors in SFPs and cigarettes can respond, so sustained outperformance depends on continued product adoption and efficient scaling. Overall, the EPS upgrade signals management confidence in product mix shift and cost leverage, but investors should weigh that against leverage, legal/regulatory exposures and the competitive landscape.

Material risks that could impair the upgraded EPS trajectory include: - Legal exposures: U.S. litigation around oral nicotine products (multiple cases) and other legacy or jurisdictional claims noted in filings. - Regulatory uncertainty: MRTP and novel‑product reviews, potential excise classifications, flavor restrictions or novel‑tobacco notifications could affect SFP adoption and profitability. - Macro and currency: Volatility in key currencies and inflationary pressure on input costs could compress margins; management cited a ~$0.04 EPS impact from certain currency moves in 2025. - Patent and litigation risk for HTU consumables: Ongoing patent disputes could influence product availability or costs in select markets. These risks do not negate the upgrade but frame the scenarios under which the company may or may not deliver the higher adjusted EPS range.